Surgery Today

, Volume 44, Issue 2, pp 285–290 | Cite as

Inhaled tiotropium to prevent postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery

  • Takashi Nojiri
  • Masayoshi Inoue
  • Kazuhiro Yamamoto
  • Hajime Maeda
  • Yukiyasu Takeuchi
  • Tomoyuki Nakagiri
  • Yasushi Shintani
  • Masato Minami
  • Noriyoshi Sawabata
  • Meinoshin Okumura
Original Article

Abstract

Purpose

A new diagnosis of chronic obstructive pulmonary disease is often made during the evaluation of patients requiring lung cancer surgery. The objective of the present study was to evaluate the clinical effects of inhaled tiotropium on the postoperative cardiopulmonary complications in patients with untreated chronic obstructive pulmonary disease requiring lung cancer surgery.

Methods

A retrospective study involving 104 consecutive patients with moderate to severe chronic obstructive pulmonary disease who underwent a lobectomy for lung cancer at two specialized thoracic centers between April 2008 and October 2011 was performed. The results were compared between patients who did and did not receive inhaled tiotropium during the perioperative period. The primary endpoint was the incidence of postoperative cardiopulmonary complications. The postoperative white blood cell counts and C-reactive protein levels as biomarkers of inflammation were also examined.

Results

The incidence of postoperative cardiopulmonary complications was significantly lower in the tiotropium group than in the control group (18 vs. 48 %, P = 0.001). Patients in the tiotropium group also showed significantly lower white blood cell counts and C-reactive protein levels postoperatively.

Conclusions

Inhaled tiotropium treatment during the perioperative period had a prophylactic effect on postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery.

Keywords

Lung cancer surgery Perioperative care Surgery Complications 

References

  1. 1.
    Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129:1305–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34:380–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63:402–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Win T, Jackson A, Sharples L, Groves AM, Wells FC, Ritchie AJ, et al. Relationship between pulmonary function and lung cancer surgical outcome. Eur Respir J. 2005;25:594–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Sekine Y, Kesler KA, Behnia M, Brooks-Brunn J, Sekine E, Brown JW. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest. 2001;120:1783–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2012) Global strategy for diagnosis, management, and prevention of COPD. 2010 (Updated). Available from http://www.goldcopd.org/. Accessed 1 June 2012.
  7. 7.
    Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, UPLIFT Study Investigators, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008;63:306–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, ATS/ERS Task Force, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.PubMedCrossRefGoogle Scholar
  11. 11.
    Nojiri T, Inoue M, Yamamoto K, Maeda H, Takeuchi Y, Funakoshi Y, et al. B-type natriuretic peptide as a predictor of postoperative cardiopulmonary complications in elderly patients undergoing pulmonary resection for lung cancer. Ann Thorac Surg. 2011;92:1051–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;14(342):d3215.CrossRefGoogle Scholar
  13. 13.
    Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Kearney DJ, Lee TH, Reilly JJ, DeCamp MM, Sugarbaker DJ. Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. Chest. 1994;105:753–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Kobayashi S, Suzuki S, Niikawa H, Sugawara T, Yanai M. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology. 2009;14:675–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Arai N, Kondo M, Izumo T, Tamaoki J, Nagai A. Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eur Respir J. 2010;35:1164–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Cosio MG, Guerassimov A. Chronic obstructive pulmonary disease: inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med. 1999;160:S21–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007;12:634–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Vacca G, Randerath WJ, Gillissen A. Inhibition of granulocyte migration by tiotropium bromide. Respir Res. 2011;12:24.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Wollin L, Pieper MP. Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm Pharmacol Ther. 2010;23:345–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risks for atrial fibrillation and congestive heart failure in patients ≥65 years of age with abnormal left ventricular diastolic relaxation. Am J Cardiol. 2004;93:54–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Nojiri T, Maeda H, Takeuchi Y, Funakoshi Y, Maekura R, Yamamoto K, et al. Predictive value of preoperative tissue Doppler echocardiographic analysis for postoperative atrial fibrillation after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2010;140:764–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Nojiri T, Maeda H, Takeuchi Y, Funakoshi Y, Maekura R, Yamamoto K, et al. Effects of inhaled tiotropium on left ventricular diastolic function in chronic obstructive pulmonary disease patients after pulmonary resection. Ann Thorac Cardiovasc Surg. 2012;18:206–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Takashi Nojiri
    • 1
    • 2
  • Masayoshi Inoue
    • 1
  • Kazuhiro Yamamoto
    • 3
  • Hajime Maeda
    • 2
  • Yukiyasu Takeuchi
    • 2
  • Tomoyuki Nakagiri
    • 1
  • Yasushi Shintani
    • 1
  • Masato Minami
    • 1
  • Noriyoshi Sawabata
    • 1
  • Meinoshin Okumura
    • 1
  1. 1.Department of General Thoracic SurgeryOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of General Thoracic SurgeryNational Hospital Organization Toneyama HospitalToyonakaJapan
  3. 3.Department of Molecular Medicine and Therapeutics Faculty of MedicineTottori University HospitalYonagoJapan

Personalised recommendations